7-溴-1H-苯并三氮唑 | 1064721-11-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 7-溴-1H-苯并三氮唑
• 中文别名: 7-溴-1H-苯并[d][1,2,3]三唑；7-溴-1H-苯并[d][1,2,3]噻唑
• 英文名称: 4-bromo-1,2,3-benzotriazole
• 英文别名: 7-Bromo-1H-benzo[d][1,2,3]triazole；4-bromo-2H-benzotriazole
• CAS: 1064721-11-4
• 化学式: C₆H₄BrN₃
• 分子量: 198.022
• InChiKey: DNJANJSHTMOQOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310
• 危险品运输编号：
  2811
• 危险性描述：
  H301

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-1H-benzo[d][1,2,3]triazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-1H-benzo[d][1,2,3]triazole
CAS number: 1064721-11-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4BrN3
Molecular weight: 198.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-1H-苯并三氮唑 在 2,2'-联吡啶 、 bis(1,5-cyclooctadiene)nickel (0) 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2,2'-dimethyl-2H,2'H-4,4'-bibenzo[d][1,2,3]triazole
  参考文献：
  名称：

  具有氧化还原活性配体的双核配合物促进共轭聚合物合成的链增长机制

  摘要：

  证明了具有氧化还原活性配体的双核镍配合物作为引发剂用于供体和受体共轭单体的链增长聚合的效用。机理分析表明，多个金属中心与氧化还原活性配体的偶联允许获得新的自由基途径，从而扩展了共轭聚合物合成的已知方法。

  DOI：

  10.1002/anie.202206044
• 作为产物：
  描述：

  2,1,3-苯并噻二唑 在 盐酸 、 氢溴酸 、 溴 、 溶剂黄146 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 6.0h， 生成 7-溴-1H-苯并三氮唑
  参考文献：
  名称：

  Synthesis and Physico-Chemical Properties in Aqueous Medium of All Possible Isomeric Bromo Analogues of Benzo-1H-Triazole, Potential Inhibitors of Protein Kinases

  摘要：

  In ongoing studies on the role of the individual bromine atoms of 4,5,6,7-tetrabromobenzotriazole (TBBt) in its relatively selective inhibition of protein kinase CK2 alpha, we have prepared all the possible two mono-, four di-, and two tri-bromobenzotriazoles and determined their physicochemical properties in aqueous medium. They exhibited a general trend of a decrease in solubility with an increase in the number of bromines on the benzene ring, significantly modulated by the pattern of substitution. For a given number of attached bromines, this was directly related to the electronic effects resulting from different sites of substitution, leading to marked variations of pK(a) values for dissociation of the triazole proton. Experimental data (pK(a), solubility) and ab initio calculations demonstrated that hydration of halogenated benzotriazoles is driven by a subtle balance of hydrophobic and polar interactions. The combination of QM-derived free energies for solvation and proton dissociations was found to be a reasonably good predictor of inhibitory activity of halogenated benzotriazoles vs CK2 alpha. Since the pattern of halogenation of the benzene ring of benzotriazole has also been shown to be one of the determinants of inhibitory potency vs some viruses and viral enzymes, the present comprehensive description of their physicochemical properties should prove helpful in efforts to elucidate reaction mechanisms, including possible halogen bonding, and the search for more selective and potent inhibitors.

  DOI：

  10.1021/jp301561x

文献信息

• [EN] DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE<br/>[FR] DÉRIVÉS DE DIAZAINDOLE ET LEUR UTILISATION DANS L'INHIBITION DE KINASE C-JUN N-TERMINALE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2010015803A1

  公开（公告）日：2010-02-11

  The invention relates to diazaindole derivatives represented by the general formula (I): where A, E, G, R1, R2, R3 and R4 are defined herein, or pharmaceutically acceptable salts thereof, their use in the inhibition of c-Jun N-terminal kinase (JNK) activity, their use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases, autoimmune diseases and/or organ failure. The invention also provides processes for the manufacture of said diazaindole derivatives and compositions containing them.

  本发明涉及由通用公式（I）表示的哒嗪吲哚衍生物：其中A、E、G、R1、R2、R3和R4在本说明书中定义，或其药用可接受的盐，它们用于抑制c-Jun N末端激酶（JNK）活性，它们用于医药领域，特别是在治疗神经退行性疾病、炎症性疾病、自身免疫性疾病和/或器官衰竭方面的应用。本发明还提供了制造所述哒嗪吲哚衍生物的方法以及包含它们的组合物。
• [EN] FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ALKERMES INC

  公开号：WO2021026375A1

  公开（公告）日：2021-02-11

  Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier and methods of treating pain in a subject in need thereof.

  本文提供了一些在治疗受试者疼痛方面有用的化合物。本文还提供了一种包含这些化合物或其药用盐的药物组合物，以及药用载体和治疗需要的受试者疼痛的方法。
• [EN] TRIAZOLE FUSED HETEROARYL COMPOUNDS AS P38 KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES FUSIONNÉS DE TRIAZOLE EN TANT QU'INHIBITEURS DE KINASE P38
  申请人：AMGEN INC

  公开号：WO2009038784A1

  公开（公告）日：2009-03-26

  The present invention comprises a new class of compounds useful for modulating the activity of p38 MAP kinase. The compounds have a general Formula (I) wherein A1, A2, A3, A4, A5, A6, R1 and R5 are defined herein. The invention further provides pharmaceutical compositions including one or more compounds of Formula (I), use of such compounds and compositions for treatment of p38 MAP kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula (I).

  本发明涵盖了一类新型化合物，用于调节p38 MAP激酶的活性。这些化合物具有一般的化学式（I），其中A1、A2、A3、A4、A5、A6、R1和R5在此处定义。本发明还提供了包括一种或多种化合物的化学式（I）的药物组合物，以及用于治疗p38 MAP激酶介导的疾病，包括类风湿性关节炎、牛皮癣和其他炎症性疾病的化合物和组合物的用途，以及用于制备化合物的中间体和有用的过程。
• [EN] INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS D'INDAZOLE ET DE PYRAZOLOPYRIDINE COMME ANTAGONISTES DU RÉCEPTEUR CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011049917A1

  公开（公告）日：2011-04-28

  Diclosed are CCRl receptor antagonists of the formula (I), wherein X is nitrogen or, C-R2; Ar1 is carbocycle, heteroaryl or heterocyclyl each optionally substituted by one to three Ra; Ar2 is carbocycle, heteroaryl or heterocyclyl, each optionally substituted by one to three Rb; Cyclic G is carbocycle, or heterocyclyl each optionally substituted by one to two R8; R1 is hydrogen, C1-6 alkyl or C 1-6 alkoxyC1-6 alkyl. Also disclosed are compositions, methods of making and using compounds of the formula (I).

  已披露的CCRl受体拮抗剂的结构式（I），其中X为氮或C-R2；Ar1为碳环、杂环芳基或杂环烷基，每个都可以选择性地被一个到三个Ra取代；Ar2为碳环、杂环芳基或杂环烷基，每个都可以选择性地被一个到三个Rb取代；环G为碳环或杂环烷基，每个都可以选择性地被一个到两个R8取代；R1为氢、C1-6烷基或C1-6烷氧基C1-6烷基。还披露了结构式（I）化合物的组合物、制备方法和使用方法。
• Does the partial molar volume of a solute reflect the free energy of hydrophobic solvation?
  作者：Anna Szymaniec-Rutkowska、Ewa Bugajska、Sławomir Kasperowicz、Kinga Mieczkowska、Agnieszka M. Maciejewska、Jarosław Poznański

  DOI：10.1016/j.molliq.2019.111527

  日期：2019.11

  thermal shift assay. According to the hierarchical clustering procedure, the excess volume, defined as the difference between the experimentally determined partial molar volume and the calculated in silico molecular volume, was found to be distant from any commonly used hydrophobicity descriptors of the ligand. The excess volume, however, properly predicts solute binding affinity. On the way, we have proved

  卤代杂环配体被广泛用作蛋白激酶的有效且经常选择性的抑制剂。然而，很少有游离配体的疏水溶剂化的确切贡献解释了有助于配体结合的自由能的相互作用的平衡。在这里，我们提出了一种基于体积数据的新实验方法，以估计配体的疏水性。我们已经针对一系列十种不同卤代的苯并三唑测试了该方法，并使用热移分析法评估了其与靶蛋白激酶CK2的结合亲和力。根据分级聚类程序，将多余体积定义为实验确定的部分摩尔体积与计算机计算得出的摩尔数之差发现分子体积与配体的任何常用疏水性描述符相距甚远。但是，过量会正确预测溶质结合亲和力。在途中，我们已经证明卤代苯并三唑与蛋白激酶CK2的结合主要是由疏水相互作用驱动的。